In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein ...

Bottom line: Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 ...

She and her colleagues recently discovered that KRAS gets mutated from another gene called FGFR2, making “those ‘early versions’ of pancreatic cancer become much more aggressive.” ...

Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA ...

Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.

The additional cohorts being enrolled include one 50-patient group made up of bile duct cancer patients who have the distinct FGFR2 fusion marker the company is honing in on and who have ...

Relay is handing off exclusive global development and commercialization rights for lirafugratinib, a fibroblast growth factor receptor 2 (FGFR2) inhibitor also known as RLY-4008, according to a ...

While the FDA approval of Truseltiq for FGFR2-positive cholangiocarcinoma was withdrawn, there are still other viable treatment options, an expert said. The Food and Drug Administration (FDA) approval ...

A new study from Cold Spring Harbor Laboratory, published in Cancer Research, shows that inhibiting the FGFR2 and EGFR proteins in pancreatic cells can delay or even prevent tumor formation.